N/A N=31 Randomized Quadruple-blind Treatment

Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy

Asthma

Bottom Line

View on ClinicalTrials.gov: NCT00200850 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2019

Primary outcome: Primary: Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment — 75.0; 69.5; 141.4; 74.8 cumulative breath units

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: House Dust Mite SLIT (Biological); High dose SLIT (Biological); Placebo SLIT (Biological)
Age: Adult · 18+ yrs
Sex: All
Sponsor: University of Wisconsin, Madison
Primary completion: Oct 2008

Outcome Measures

Outcome	Result	p-value
PRIMARY Bronchial Threshold to Allergen Challenge From Baseline to 12-18 Months of Treatment	75.0; 69.5; 141.4; 74.8; 100.9; 83.3	—

Summary

This study will investigate sublingual immunotherapy (SLIT), a treatment involving antigens placement under the tongue to help asthma sufferers build a tolerance to the allergy-causing substances. Specifically, this study will determine the effectiveness of SLIT at two different dosing regimens for patients with intermittent mild asthma caused by dust mites.

Eligibility Criteria

Inclusion Criteria

House dust mite-induced allergic rhinitis/mild intermittent asthma

Exclusion Criteria

Use of previous allergy immunotherapy for house dust mite asthma
Pregnancy or breastfeeding

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00200850). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.